Cargando…
A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial
BACKGROUND: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkh...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611180/ https://www.ncbi.nlm.nih.gov/pubmed/31333730 http://dx.doi.org/10.4103/jrms.JRMS_543_18 |
_version_ | 1783432641021739008 |
---|---|
author | Dehnavi, Sajad Azad, Farahzad Jabbari Hoseini, Reza Farid Moazzen, Nasrin Tavakkol-Afshari, Jalil Nikpoor, Amin Reza Salmani, Amir Abbas Ahanchian, Hamid Mohammadi, Mojgan |
author_facet | Dehnavi, Sajad Azad, Farahzad Jabbari Hoseini, Reza Farid Moazzen, Nasrin Tavakkol-Afshari, Jalil Nikpoor, Amin Reza Salmani, Amir Abbas Ahanchian, Hamid Mohammadi, Mojgan |
author_sort | Dehnavi, Sajad |
collection | PubMed |
description | BACKGROUND: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkhead box P3 (FoxP3) in AR patients who received concomitant immunotherapy in a placebo-controlled clinical trial. MATERIALS AND METHODS: Twenty AR patients were randomized in synbiotic and placebo groups and received cluster immunotherapy for 2 months. RNA was extracted from peripheral PBMCs, then the cDNA synthesized. Subsequently, SYBR Green real-time Reverse transcription polymerase chain reaction technique was employed for studying the expression of mentioned genes. In addition, SNOT-22 and mini-Rhinoconjunctivitis Quality of Life Questionnaire questionnaires were completed by patients. Data were analyzed before and also 2 and 6 months after intervention. RESULTS: Clinical symptoms and quality of life were improved with immunotherapy, but there was no significant difference between the placebo and synbiotic groups. Gene expression of IFN-γ, TGF-β, and FoxP3 was increased whereas the gene expression of IL-4 and IL-10 decreased, but not significant. Interestingly, the gene expression of IL-17 in the synbiotic group was significantly decreased versus placebo after 2 months (P = 0.001) and also at the end of intervention (P = 0.0001) comparing with the time zero. CONCLUSION: Significant reduction in the IL-17 gene expression following administration of synbiotic versus placebo shows the importance of synbiotic in control of the immunopathogenesis of AR. Further studies with more samples are recommended. In addition, evaluating the effects of synbiotic in patients who do not undergo immunotherapy is suggested to get a better conclusion. |
format | Online Article Text |
id | pubmed-6611180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-66111802019-07-22 A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial Dehnavi, Sajad Azad, Farahzad Jabbari Hoseini, Reza Farid Moazzen, Nasrin Tavakkol-Afshari, Jalil Nikpoor, Amin Reza Salmani, Amir Abbas Ahanchian, Hamid Mohammadi, Mojgan J Res Med Sci Original Article BACKGROUND: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkhead box P3 (FoxP3) in AR patients who received concomitant immunotherapy in a placebo-controlled clinical trial. MATERIALS AND METHODS: Twenty AR patients were randomized in synbiotic and placebo groups and received cluster immunotherapy for 2 months. RNA was extracted from peripheral PBMCs, then the cDNA synthesized. Subsequently, SYBR Green real-time Reverse transcription polymerase chain reaction technique was employed for studying the expression of mentioned genes. In addition, SNOT-22 and mini-Rhinoconjunctivitis Quality of Life Questionnaire questionnaires were completed by patients. Data were analyzed before and also 2 and 6 months after intervention. RESULTS: Clinical symptoms and quality of life were improved with immunotherapy, but there was no significant difference between the placebo and synbiotic groups. Gene expression of IFN-γ, TGF-β, and FoxP3 was increased whereas the gene expression of IL-4 and IL-10 decreased, but not significant. Interestingly, the gene expression of IL-17 in the synbiotic group was significantly decreased versus placebo after 2 months (P = 0.001) and also at the end of intervention (P = 0.0001) comparing with the time zero. CONCLUSION: Significant reduction in the IL-17 gene expression following administration of synbiotic versus placebo shows the importance of synbiotic in control of the immunopathogenesis of AR. Further studies with more samples are recommended. In addition, evaluating the effects of synbiotic in patients who do not undergo immunotherapy is suggested to get a better conclusion. Wolters Kluwer - Medknow 2019-06-25 /pmc/articles/PMC6611180/ /pubmed/31333730 http://dx.doi.org/10.4103/jrms.JRMS_543_18 Text en Copyright: © 2019 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Dehnavi, Sajad Azad, Farahzad Jabbari Hoseini, Reza Farid Moazzen, Nasrin Tavakkol-Afshari, Jalil Nikpoor, Amin Reza Salmani, Amir Abbas Ahanchian, Hamid Mohammadi, Mojgan A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial |
title | A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial |
title_full | A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial |
title_fullStr | A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial |
title_full_unstemmed | A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial |
title_short | A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial |
title_sort | significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: a placebo-controlled clinical trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611180/ https://www.ncbi.nlm.nih.gov/pubmed/31333730 http://dx.doi.org/10.4103/jrms.JRMS_543_18 |
work_keys_str_mv | AT dehnavisajad asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT azadfarahzadjabbari asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT hoseinirezafarid asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT moazzennasrin asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT tavakkolafsharijalil asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT nikpooraminreza asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT salmaniamirabbas asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT ahanchianhamid asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT mohammadimojgan asignificantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT dehnavisajad significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT azadfarahzadjabbari significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT hoseinirezafarid significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT moazzennasrin significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT tavakkolafsharijalil significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT nikpooraminreza significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT salmaniamirabbas significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT ahanchianhamid significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial AT mohammadimojgan significantdecreaseinthegeneexpressionofinterleukin17followingtheadministrationofsynbioticinpatientswithallergicrhinitiswhounderwentimmunotherapyaplacebocontrolledclinicaltrial |